KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Receivables (2016 - 2025)

Gilead Sciences (GILD) has disclosed Change in Receivables for 17 consecutive years, with -$179.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 148.61% year-over-year to -$179.0 million, compared with a TTM value of $367.0 million through Dec 2025, up 364.03%, and an annual FY2025 reading of $367.0 million, up 364.03% over the prior year.
  • Change in Receivables was -$179.0 million for Q4 2025 at Gilead Sciences, down from $333.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $612.0 million in Q3 2023 and bottomed at -$975.0 million in Q1 2021.
  • Average Change in Receivables over 5 years is $8.2 million, with a median of $47.5 million recorded in 2024.
  • The sharpest move saw Change in Receivables crashed 359.31% in 2021, then surged 906.9% in 2025.
  • Year by year, Change in Receivables stood at -$41.0 million in 2021, then surged by 785.37% to $281.0 million in 2022, then crashed by 178.29% to -$220.0 million in 2023, then skyrocketed by 67.27% to -$72.0 million in 2024, then plummeted by 148.61% to -$179.0 million in 2025.
  • Business Quant data shows Change in Receivables for GILD at -$179.0 million in Q4 2025, $333.0 million in Q3 2025, and $292.0 million in Q2 2025.